Status:
UNKNOWN
Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
Lead Sponsor:
University Hospital, Caen
Conditions:
Advanced or Metastatic Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
To date, Sorafenib is the only drug therapy to have demonstrated a benefit in overall survival in patients with advanced or metastatic hepatocellular carcinoma. However, this treatment causes many adv...
Eligibility Criteria
Inclusion
- Major Patients.
- Patients with hepatocellular carcinoma on cirrhosis.
- Patients treated for the first time with sorafenib for hepatocellular carcinoma.
- Informed information about the study.
Exclusion
- Patients with contraindications to sorafenib.
- Pregnant or lactating woman
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03340636
Start Date
January 1 2018
End Date
March 1 2019
Last Update
November 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen University Hospital
Caen, France